TrialHuman vaccines & immunotherapeutics2021

Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Ravish H S et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.